Cargando…
COVID-19 Vaccine-Related Vogt–Koyanagi–Harada Disease Complicated by Central Serous Chorioretinopathy during Treatment Course: Case Report and Literature Review
With the promotion of mass COVID-19 vaccination in the elimination of the SARS-CoV-2 pandemic, new side effects, including ocular complications, are emerging. In this study, we report on a 62-year-old Chinese man who developed Vogt–Koyanagi–Harada (VKH) disease six days after his third dose of an in...
Autores principales: | Han, Ruyi, Xu, Gezhi, Ding, Xinyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698606/ https://www.ncbi.nlm.nih.gov/pubmed/36366301 http://dx.doi.org/10.3390/vaccines10111792 |
Ejemplares similares
-
Comparison of the Clinical Manifestations between Acute Vogt-Koyanagi-Harada Disease and Acute Bilateral Central Serous Chorioretinopathy
por: Shin, Woo Beom, et al.
Publicado: (2015) -
Comparison of the optical coherence tomographic characters between acute Vogt-Koyanagi-Harada disease and acute central serous chorioretinopathy
por: Lin, Dusheng, et al.
Publicado: (2014) -
Atypical Chronic Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease: Full Therapeutic Response to Half-Fluence Photodynamic Therapy
por: Yanık, Özge, et al.
Publicado: (2022) -
Treatment of Vogt-Koyanagi-Harada Disease
por: Alaql, Musab K, et al.
Publicado: (2020) -
Tofacitinib in Vogt-Koyanagi-Harada disease
por: Dutta Majumder, Parthopratim, et al.
Publicado: (2020)